Geron Receives Fast Track Designation to Imetelstat for Myelofibrosis

More possible good news for upcoming therapies for myeloproliferative neoplasms. Geron was granted fast-track designation by FDA for imetelstat, which they have pursued in people with Intermediate-2 Myelofibrosis OR who have relapsed after or who are refractory to a JAK inhibitor such as Jakafi or Inrebic.

About Imetelstat

Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Ongoing clinical studies of imetelstat consist of IMerge, a Phase 2/3 trial in lower-risk myelodysplastic syndromes (MDS), and IMbark, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis (MF). Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower-risk MDS who are refractory or resistant to an erythropoiesis-stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to Janus kinase (JAK) inhibitor treatment.


Click here to read the full press release


Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.



Get free, timely information on living with an MPN.